Compassionate access to virus-specific T cells for adoptive immunotherapy over 15 years.
Michelle A Neller, George R Ambalathingal, Nada Hamad...
https://pubmed.ncbi.nlm.nih.gov/39627190/Actively Recruiting
Led by LucasBio · Updated on 2026-07-06
6
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating the safety and effectiveness of a therapy called Multi-Virus Specific T cells LB-DTK-MV in children and young adults aged 1 to 25 years who have systemic viral infections such as CMV, EBV, and BKV after receiving allogeneic hematopoietic stem cell transplantation. The study aims to determine the maximum tolerated dose of LB-DTK-MV, identify any adverse events within two weeks after the second infusion, and assess reductions in viral loads and improvements in symptoms within the same timeframe. Participants will receive two intravenous infusions of LB-DTK-MV at either a low dose 1x107m2 or a high dose 2x107m2. The first infusion occurs at the baseline visit, followed by a second infusion 14 days later at the same dose. This treatment period is followed by weekly clinic visits for six months to monitor participants responses and safety. During the study, participants will undergo regular assessments including viral load measurements, immunogenicity testing, and monitoring for adverse events from enrollment through 24 weeks after treatment starts. The researchers will track clinical symptoms and laboratory tests to evaluate treatment effects and safety over this period. The total participation duration extends up to six months with close follow-up care to observe outcomes and any treatment-related effects.
CONDITIONS
Evaluation of Safety and Efficacy of Virus Specific T-Cell Administration in Pediatric Patients With Systemic Viral Infection Following Allogeneic Hematopoietic Stem Cell Transplantation.
N
Nayoun Kim, Ph.D.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
LucasBio
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening visit
Duration - 14 days between infusions
Participants receive two intravenous infusions of LB-DTK-MV at either a low or high dose, with the second infusion given 14 days after the first.
2 infusion visits
Duration - 6 months
Participants attend weekly follow-up visits for six months to monitor viral loads, immune response, and any side effects.
Weekly clinic visits
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Michelle A Neller, George R Ambalathingal, Nada Hamad...
https://pubmed.ncbi.nlm.nih.gov/39627190/Jing Liu, Ying-Jun Chang, Chen-Hua Yan...
https://pubmed.ncbi.nlm.nih.gov/27311748/Mrinali Patel Gupta, Peter Coombs, Susan E Prockop...
https://pubmed.ncbi.nlm.nih.gov/25559515/Sanjeet S Dadwal, Rajat Bansal, Michael W Schuster...
https://pubmed.ncbi.nlm.nih.gov/38593233/Corey Smith, Leone Beagley, Sweera Rehan...
https://pubmed.ncbi.nlm.nih.gov/29982441/Baran Alkan, M Asli Tuncer, A Çağkan İnkaya
https://pubmed.ncbi.nlm.nih.gov/39245328/K Cwynarski, J Ainsworth, M Cobbold...
https://pubmed.ncbi.nlm.nih.gov/11222365/Claudio Annaloro, Fabio Serpenti, Giorgia Saporiti...
https://pubmed.ncbi.nlm.nih.gov/33552044/Stephen P Hunger, Charles G Mullighan
https://pubmed.ncbi.nlm.nih.gov/26465987/Nicolas Lambert, Majdouline El Moussaoui, Frédéric Baron...
https://pubmed.ncbi.nlm.nih.gov/37515196/LucasBio
Lead Sponsor